CLAIMS

1. A pharmaceutical formulation in the form of a tablet comprising *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, microcrystalline cellulose (MCC) and dicalcium phosphate anhydrous (DCPA).

2. An immediate release ~~pharmaceutical formulation~~tablet according to claim 1.

3. A ~~pharmaceutical formulation~~tablet according to any preceding claim wherein the amount of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine is up to 60% w/w.

4. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, wherein the amount of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine is 27% w/w.

5. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, wherein the ratio of MCC to DCPA is from 3:1 to 2:3.

6. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, wherein the ratio of MCC to DCPA is from 3:1 to 3:2.

7. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, wherein the combined amount of MCC and DCPA is from 15% w/w to 85% w/w.

8. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, wherein the combined amount of MCC and DCPA is from 40% w/w to 85% w/w.

9. A tablet ~~pharmaceutical formulation~~ according to any preceding claim, further comprising at least one additional disintegrant in an amount of up to 10% w/w, optionally wherein the disintegrant is selected from croscarmellose sodium, crospovidine and sodium starch glycolate.

10. A tablet ~~pharmaceutical formulation~~ according to claim 9, wherein the at least one additional disintegrant is sodium starch glycolate.

11. A tablet~~pharmaceutical formulation~~ according to claim 9 or claim 10, wherein the at least one additional disintegrant is present in an amount of up to 5% w/w.

12. A tablet~~pharmaceutical formulation~~ according to any preceding claim, further comprising at least one lubricant in an amount of up to 4% w/w, optionally wherein the disintegrant is selected from magnesium stearate, calcium stearate and sodium stearyl fumarate (SSF).

13. A tablet~~pharmaceutical formulation~~ according to claim 12, wherein the at least one lubricant is magnesium stearate.

14. A tablet~~pharmaceutical formulation~~ according to claim 12 or claim 13, wherein the at least one lubricant is present in an amount of up to 1.5% w/w.

~~15. A pharmaceutical formulation according to any preceding claim in the form of a tablet, optionally wherein the tablet is coated.~~

~~16~~15. A tablet according to any preceding claim ~~15~~ containing 25 mg, 50 mg or 100 mg of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine.

~~17. A capsule containing a pharmaceutical formulation according to any of claims 1 to 14.~~

~~18~~16. A process for manufacturing a tablet according to any of claims ~~15~~ 1 to 14 comprising the steps of:
i) dry granulating *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine with MCC and DCPA to form a blend; and
ii) compressing the blend into a tablet.

~~19~~17. A process according to claim ~~18~~ 16 wherein the compression into tablets is performed by roller compaction.

~~20~~18. A continuous direct compression process according to claim ~~18~~ 16 or claim ~~19~~17.